What are NLRP3 inflammasome inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NLRP3 inflammasome inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting NLRP3). 0 are currently marketed, with 4 more in clinical development.

NLRP3 inflammasome inhibitor

0 marketed 2 in Phase 3 2 in Phase 2

This page covers all NLRP3 inflammasome inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting NLRP3.

Targets

NLRP3

Phase 3 pipeline (2)

BMS-986278 · Bristol-Myers Squibb · Immunology
BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.
BMS-986205 · Bristol-Myers Squibb · Immunology
BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.

Phase 2 pipeline (2)

AQX-1125 · Aquinox Pharmaceuticals (Canada) Inc. · Rheumatology
AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome.
ASP1517 · Astellas Pharma Inc · Inflammation
ASP1517 is a selective and potent inhibitor of the NLRP3 inflammasome.